Capecitabine Oral Product

DRUG4 trials

Sponsors

Instituto Nacional de Cancer, Brazil, Herui Yao, Abramson Cancer Center at Penn Medicine, Gilead Sciences

Conditions

Metastatic Breast CancerNeuroendocrine Tumor Grade 2Neuroendocrine TumorsRectal Neoplasm Malignant

Phase 2

Capecitabine Versus Bolus 5-Fu Associated to Radiotherapy as Neoadjuvant Treatment for Rectal Cancer.

CompletedNCT03428529

Instituto Nacional de Cancer, BrazilRectal Neoplasm Malignant

Start: 2011-01-12End: 2016-12-13Updated: 2018-02-09

CapTemY90 for Grade 2/3 NET Liver Metastases

RecruitingNCT04339036

Abramson Cancer Center at Penn MedicineNeuroendocrine Tumor Grade 2, Neuroendocrine Tumors

Start: 2021-10-07End: 2026-05-01Target: 70Updated: 2025-12-10

Phase 3

Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

RecruitingNCT04263298

Herui YaoMetastatic Breast Cancer

Start: 2018-05-01End: 2030-05-01Target: 210Updated: 2022-09-30

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Active, not recruitingNCT04639986

Gilead SciencesMetastatic Breast Cancer

Start: 2020-11-23End: 2026-12-01Updated: 2026-02-09

Related Papers

Sacituzumab govitecan in HR<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.

2024-10-0125 citations

Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors.

2024-04-0517 citations

ArTisaN trial protocol: a single Centre, open-label, phase II trial of the safety and efficacy of TheraSphere selective internal radiation therapy (SIRT) in the treatment of inoperable metastatic (liver) neuroendocrine neoplasia (NENs).

2022-07-201 citations

Quality of life in a randomized trial comparing two neoadjuvant regimens for locally advanced rectal cancer-INCAGI004.

2022-04-292 citations

Clinical Evidence of Chemotherapy or Endocrine Therapy Maintenance in Patients with Metastatic Breast Cancer: Meta-Analysis of Randomized Clinical Trials and Propensity Score Matching of Multicenter Cohort Study.

2022-02-041 citations